



10/715,331

=>

Uploading C:\Program Files\Stnexp\Queries\10715331.str



chain nodes :
7 8 9 11 14 16
ring nodes :
1 2 3 4 5 6
ring/chain nodes :
10 15
chain bonds :
1-8 2-10 3-16 4-7 6-11 8-9 8-14 14-15
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-2 1-6 1-8 2-3 3-4 4-5 4-7 5-6 8-9 8-14 14-15
exact bonds :
2-10 3-16 6-11
isolated ring systems :
containing 1 :

G1:O,CH2

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 14:CLASS 15:CLASS 16:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 O,CH2

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 20:05:33 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 9 TO ITERATE

100.0% PROCESSED 9 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**



PROJECTED ITERATIONS: 9 TO 360

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=>

Uploading C:\Program Files\Stnexp\Queries\10715331 (a).str



chain nodes :
 7 8 9 10 13 15
 ring nodes :
 1 2 3 4 5 6
 ring/chain nodes :
 14
 chain bonds :
 1-8 3-15 4-7 6-10 8-9 8-13 13-14
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6
 exact/norm bonds :
 1-2 1-6 1-8 2-3 3-4 4-5 4-7 5-6 8-9 8-13 13-14
 exact bonds :
 3-15 6-10
 isolated ring systems :
 containing 1 :

G1:O,CH2

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
 13:CLASS 14:CLASS 15:CLASS


10/715,331

L3 STRUCTURE UPLOADED

=> d 13

L3 HAS NO ANSWERS

L3 STR



G1 O,CH2

Structure attributes must be viewed using STN Express query preparation.

=> s 13 sss sam

SAMPLE SEARCH INITIATED 20:06:49 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 9 TO ITERATE

100.0% PROCESSED 9 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 9 TO 360

PROJECTED ANSWERS: 0 TO 0

L4 0 SEA SSS SAM L3

=> s 13 sss ful

FULL SEARCH INITIATED 20:07:00 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 190 TO ITERATE

100.0%/PROCESSED 190 ITERATIONS

15 ANSWERS

SEARCH TIME: 00.00.01

L5 15 SEA SSS FUL L3

=> => d his

(FILE 'HOME' ENTERED AT 20:04:56 ON 21 JUN 2007)

10/715,331

FILE 'REGISTRY' ENTERED AT 20:05:04 ON 21 JUN 2007

```
L1      STRUCTURE UPLOADED
L2      0 S L1 SSS SAM
L3      STRUCTURE UPLOADED
L4      0 S L3 SSS SAM
L5      15 S L3 SSS FUL
```

FILE 'CAPLUS' ENTERED AT 20:07:07 ON 21 JUN 2007

=> s 15

L6 11 L5


=> d 16 1-11 bib,ab,hitstr

L6 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:802605 CAPLUS
 DN 141:314624
 TI Compositions and methods related to fatty amino acid derivatives
 IN Lakner, Frederick J.; Negrete, George R.
 PA Board of Regents, the University of Texas System, USA
 SO U.S. Pat. Appl. Publ., 13 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

Appl.


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004192894	A1	20040930	US 2003-715331	20031117
PRAI	US 2002-426686P	P	20021115		
OS	CASREACT 141:314624; MARPAT 141:314624				
AB	The present invention concerns the use of methods and/or compns. related to the synthesis and use of fatty asparagine, cysteine and/or serine derivs. I [R1, R2 = (un)branched, (un)saturated hydrocarbon, cholesterol, steroid, aromatic; X = O, CH2], II and III, resp., or their carboxylate salts. In particular, the invention concerns methods and compns. for the production of liposomes including fatty asparagine, cysteine and/or serine derivs.				
IT	765301-17-5P RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (compns. and methods related to fatty amino acid derivs.)				
RN	765301-17-5 CAPLUS				
CN	4-Pyrimidinecarboxylic acid, hexahydro-2-octyl-6-oxo-3-(1-oxooctadecyl)-, (2S,4S)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



IT 765956-24-9P, (S,S)-3-Octadecanoyl-6-oxo-2-undecylhexahydropyrimidine-4-carboxylic acid
 RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and liposome formation of; compns. and methods related to fatty amino acid derivs.)
 RN 765956-24-9 CAPLUS
 CN 4-Pyrimidinecarboxylic acid, hexahydro-6-oxo-3-(1-oxooctadecyl)-2-undecyl-, (2S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 765301-21-1P


RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);
BIOL (Biological study); PREP (Preparation)

(preparation and liposome formation with; compns. and methods related to
fatty amino acid derivs.)

RN 765301-21-1 CAPLUS


CN 1,6(2H)-Pyrimidinedicarboxylic acid, tetrahydro-4-oxo-2-undecyl-,
1-undecyl ester, (2S,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1999:604219 CAPLUS
 DN 131:351625
 TI Enantiomerically Pure Tetrahydropyrimidinones in Asymmetric Synthesis:
 Preparation of a Protected α -Methylasparagine Derivative and
 Corresponding Dipeptides
 AU Hopkins, Stephanie A.; Ritsema, Todd A.; Konopelski, Joseph P.
 CS Department of Chemistry and Biochemistry, University of California, Santa
 Cruz, CA, 95064, USA
 SO Journal of Organic Chemistry (1999), 64(21), 7885-7889
 CODEN: JOCEAH; ISSN: 0022-3263
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 131:351625
 AB Me ester (I), available in enantiomerically pure form from the amino acid
 asparagine via a one-pot cyclization/protection sequence, followed by
 esterification, can be effectively deprotonated with LDA/DMPU/LiCl.
 Treatment with MeI affords the corresponding alkylated adduct in
 enantiomerically pure form, from which α -methylaspartic acid is
 obtained. Variation of the amine protection group allows for the
 isolation of a protected carboxylic acid/free amine derivative of
 α -methylasparagine. The utility of H-MeAsn-OMe is demonstrated in
 the formation of dipeptides.
 IT 250264-83-6P 250264-85-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and reaction of in the preparation of a protected
 α -methylasparagine derivative and corresponding dipeptides from
 enantiomerically pure tetrahydropyrimidinones)
 RN 250264-83-6 CAPLUS
 CN 1,6(2H)-Pyrimidinedicarboxylic acid, 2-(4-chlorophenyl)tetrahydro-4-oxo-,
 1-methyl ester, (2S,6S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 250264-85-8 CAPLUS
 CN 1,6(2H)-Pyrimidinedicarboxylic acid, 2-(4-chlorophenyl)tetrahydro-4-oxo-,
 1-(2-propenyl) ester, (2S,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/715,331




RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1996:72956 CAPLUS
 DN 124:233058
 TI Synthesis of enantiomerically pure β -amino acids from
 2-tert-butyl-1-carbomethoxy-2,3-dihydro-4(1H)-pyrimidinone:
 (R)-3-amino-3-(p-methoxyphenyl)propionic acid (1(2H)-pyrimidinecarboxylic
 acid, 2-(1,1-dimethylethyl)-3,4-dihydro-4-oxo-, methyl ester, (R)- or
 (S)-)
 AU Lakner, F. J.; Chu, K. S.; Negrete, G. R.; Konopelski, J. P.
 CS Dep. Chem. and Biochem., Univ. California, Santa Cruz, CA, 95064, USA
 SO Organic Syntheses (1996), 73, 201-14
 CODEN: ORSYAT; ISSN: 0078-6209
 PB Wiley
 DT Journal
 LA English
 OS CASREACT 124:233058
 AB Cyclocondensation of L-Asn with pivaldehyde, followed by acylation with
 ClCO₂Me, gave tetrahydropyrimidinecarboxylic acid I. Electrochem.
 oxidative decarboxylation and elimination of I gave dihydropyrimidinone
 II, which underwent stereoselective palladium-catalyzed addition of
 4-MeOC₆H₄I to give III, which was reduced to the cis-
 tetrahydropyrimidinone and hydrolyzed with acid to give the title
 (R)- β -amino acid IV.
 IT 138723-45-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (asym. synthesis of β -amino acids from chiral, asparagine-derived
 dihydropyrimidinones)
 RN 138723-45-2 CAPLUS
 CN 1,6(2H)-Pyrimidinedicarboxylic acid, 2-(1,1-dimethylethyl)tetrahydro-4-oxo-
 , 1-methyl ester, (2S-cis)- (9CI) (CA INDEX NAME)


Same as
4

Absolute stereochemistry.



L6 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1992:106718 CAPLUS
 DN 116:106718
 TI Enantiomerically pure dihydropyrimidinones as reagents and auxiliaries for asymmetric synthesis
 AU Chu, Kent S.; Negrete, George R.; Konopelski, Joseph P.; Lakner, Frederick J.; Woo, Nam Tae; Olmstead, Marilyn M.
 CS Dep. Chem. Biochem., Univ. California, Santa Cruz, CA, 95064, USA
 SO Journal of the American Chemical Society (1992), 114(5), 1800-12
 CODEN: JACSAT; ISSN: 0002-7863
 DT Journal
 LA English
 OS CASREACT 116:106718
 AB The full exptl. details of the synthesis, structure, and reactivity of (R)- and (S)-2-tert-butyl-1-carbomethoxy-2,3-dihydropyrimidin-4(1H)-one (I) are reported. The synthesis employs asparagine as the starting material and provides I in 55% yield without the need for chromatog. purification. The structure of (R)-I, as determined by x-ray crystallog., demonstrates significant pyramidalization at the C4 (carbonyl) and N1 centers, with little evidence of conjugation of N1 with the α,β -unsatd. (vinylogous urea) system. In contrast, 2-tert-butyl-3-[(S)-O-methylmandeloyl]-2,3-dihydropyrimidin-4(1H)-one (II) shows strong coupling of N1 to the α,β -unsatd. system, as evidenced by changes in bond lengths and torsional angles. Compound I has proven useful as a reagent for the synthesis of enantiomerically pure β -aryl- β -amino acids. The key step in this protocol is the palladium-catalyzed conjugate addition of aryl iodides to I. Evidence is presented to support a mechanism for this reaction that involves an unprecedented transannular hydride transfer into the palladium coordination sphere. In addnl. expts., I has been employed as an auxiliary for the synthesis of enantiomerically pure α -substituted carboxylic acids. The crystalline properties of I and many of its derivs. allows for simplified purification procedures to be utilized.
 IT 138723-45-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and oxidative decarboxylation of)
 RN 138723-45-2 CAPLUS
 CN 1,6(2H)-Pyrimidinedicarboxylic acid, 2-(1,1-dimethylethyl)tetrahydro-4-oxo-, 1-methyl ester, (2S-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 138723-44-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and oxidative decarboxylation of, cyclization in)
 RN 138723-44-1 CAPLUS
 CN 1,6(2H)-Pyrimidinedicarboxylic acid, 2-(1,1-dimethylethyl)tetrahydro-4-oxo-, 1-(phenylmethyl) ester, (2S-cis)- (9CI) (CA INDEX NAME)

10/715,331


Absolute stereochemistry.



L6 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1991:102828 CAPLUS
 DN 114:102828
 TI Self-reproduction of chirality. Asymmetric synthesis of
 β -aryl- β -amino acids from enantiomerically pure
 dihydropyrimidinones
 AU Konopelski, Joseph P.; Chu, Kent S.; Negrete, George R.
 CS Dep. Chem., Univ. California, Santa Cruz, CA, 95064, USA
 SO Journal of Organic Chemistry (1991), 56(4), 1355-7
 CODEN: JOCEAH; ISSN: 0022-3263
 DT Journal
 LA English
 OS CASREACT 114:102828
 AB Enantiomerically pure dihydropyrimidinone I can be prepared
 stereospecifically and in good yield from the amino acid asparagine.
 Compound I reacts with aryl iodides in the presence of catalytic amts. of
 Pd(OAc)₂ and added phosphine to afford dihydropyrimidinones, e.g. II, in
 which the aryl group has been added stereospecifically to the
 β -carbon of the original α,β -unsatd. system. Application
 of this methodol. to the synthesis of a protected version of the
 tripeptide portion III (Boc = Me₃CO₂C) of the natural product
 jasplakinolide is presented.
 IT 131791-84-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and oxidative decarboxylation of, dihydropyrimidinone from)
 RN 131791-84-9 CAPLUS
 CN 1,6(2H)-Pyrimidinedicarboxylic acid, 2-(1,1-dimethylethyl)tetrahydro-4-oxo-
 , 1-methyl ester, monopotassium salt, (2S-cis)- (9CI) (CA INDEX NAME)

Same as
#4

Absolute stereochemistry.



● K

L6 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1984:551870 CAPLUS
 DN 101:151870

TI (Hexahydropyrimidyl)thiopropionimidic acid derivatives.

IN Corbiere, Jerome

PA Fr.

SO PCT Int. Appl., 25 pp.

CODEN: PIXXD2

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8401384	A1	19840412	WO 1982-FR158	19820928
	W: JP, US				
	RW: BE, CH, DE, FR, GB, LU, NL				
	EP 119994	A1	19841003	EP 1982-902819	19820928
	R: BE, CH, DE, FR, GB, LI, LU, NL				
PRAI	WO 1982-FR158	A	19820928		

OS MARPAT 101:151870


AB Title compds. I (Z = O, S; R = H, CO₂CH₂Ph; R₁, R₂, and R₃ are H, alkyl; R₄ = H, alkyl, aryl, aralkyl) were prepared as antihypertensives (no data). Thus, nitrile oxide II was treated with H₂S and the resulting product was deprotected by BF₃ and the saponified to give I (Z = O, R = R₁ = R₂ = R₄ = H, R₃ = Me).

IT 84845-22-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 84845-22-7 CAPLUS

CN 4-Pyrimidinecarboxylic acid, hexahydro-3-[3-(hydroxyamino)-1-oxo-3-thioxopropyl]-6-oxo-2-thioxo- (9CI) (CA INDEX NAME)



L6 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1983:594996 CAPLUS
 DN 99:194996
 TI Hexahydro-6-oxo-4S-pyrimidinecarboxylic acids
 PA Otsuka Pharmaceutical Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 7 pp.
 CODEN: JKXXAF

DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 58110573	A	19830701	JP 1981-210369	19811225
	JP 61023185	B	19860604		
PRAI	JP 1981-210369		19811225		

OS CASREACT 99:194996

AB Hexahydropyrimidines I (R = H, Me; R1 = H, Ac, Bz), useful as antihypertensives (no data), were prepared by acylating hexahydro-6-oxopyrimidine-4S-carboxylic acid (II). Thus, 4.9 g II dissolved in aqueous NaHCO₃ and acylated with 6.1 g 3-acetylthio-2S-methylpropanoyl chloride gave 3 g I (R = 2S-Me, R1 = Ac), which was converted to its dicyclohexylamine salt. Both were hydrolyzed with 14% NH₄OH at room temperature to give I (R = 2S-Me, R1 = H) and its dicyclohexylamine salt, resp.


IT 87746-26-7P 87746-27-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 87746-26-7 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 3-[3-(benzoylthio)-1-oxopropyl]hexahydro-6-oxo-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 87746-27-8 CAPLUS

CN 4-Pyrimidinecarboxylic acid, hexahydro-3-(3-mercapto-1-oxopropyl)-6-oxo-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1983:107316 CAPLUS
 DN 98:107316
 TI Orotic acid derivatives and therapeutic compositions containing them
 IN Corbiere, Jerome
 PA Fr.
 SO Fr. Demande, 22 pp.
 CODEN: FRXXBL
 DT Patent
 LA French
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2505333	A1	19821112	FR 1981-9057	19810507
	FR 2505333	B3	19840803		
	WO 8401385	A1	19840412	WO 1982-FR159	19820928

W: JP, US

RW: BE, CH, DE, FR, GB, LU, NL

EP 119995	A1	19841003	EP 1982-902820	19820928
-----------	----	----------	----------------	----------

R: BE, CH, DE, FR, GB, LI, LU, NL

PRAI	FR 1981-9057		19810507	
------	--------------	--	----------	--

	WO 1982-FR159	A	19820928	
--	---------------	---	----------	--

OS CASREACT 98:107316; MARPAT 98:107316


AB Thiohydroxamic acids I (R, R2, R4 = H, alkyl; R1 = H, CO2CH2Ph; R3 = H, alkyl, aryl, aralkyl; X = O, S) were prepared Thus II (R1 = R4 = R5 = H) was esterified and benzyloxycarbonylated to give II (R1 = CO2CH2Ph, R4 = Me, R5 = H) which was treated with HO2CCHMeCN to give II (R1 = CO2CH2Ph, R4 = Me, R5 = COCHMeCM, III). III was oxidized to N-oxide and treated with H2S to give I (R = R3 = H, R1 = CO2CH2Ph, R2 = R4 = Me, X = O) which was deblocked in 2 steps to give I (R = R1 = R3 = R4 = H, R2 = Me, X = O). I gave 75% inhibition of angiotensin-induced vasoconstriction in rats at 0.5-1.5 mg.

IT 84845-22-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 84845-22-7 CAPLUS

CN 4-Pyrimidinecarboxylic acid, hexahydro-3-[3-(hydroxyamino)-1-oxo-3-thioxopropyl]-6-oxo-2-thioxo- (9CI) (CA INDEX NAME)




L6 ANSWER 9 OF 11. CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1983:72129 CAPLUS
 DN 98:72129
 TI Acyl derivatives of dihydroorotic acid and their use as medicaments
 IN Corbiere, Jerome
 PA Fr.
 SO Fr. Demande, 14 pp.
 CODEN: FRXXBL
 DT Patent
 LA French
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2501205	A1	19820910	FR 1981-4589	19810309
	FR 2501205	B3	19840106		
PRAI	FR 1981-4589		19810309		
OS	CASREACT 98:72129; MARPAT 98:72129				
AB	Orotic acid derivs. I (R = H, CHPh2, CPh3; Z = O, S; R1 = H, alkyl; R2 = alkyl), useful as antihypertensives (no data, formulations are given), were prepared II (R = CPh3, R3 = cyano, R4 = Me) reacted with NH3, the II [R = CPh3, R3 = C(:NH)NH2, R4 = Me] obtained was converted to II [R = H, R3 = C(:NH)NH2, R4 = Me], and the latter was saponified to I (R = R2 = H, Z = O, R1 = Me).				
IT	84591-04-8P 84591-05-9P 84591-06-0P RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)				
RN	84591-04-8 CAPLUS				
CN	4-Pyrimidinecarboxylic acid, 3-(3-amino-3-imino-1-oxopropyl)hexahydro-6-oxo-2-thioxo- (9CI) (CA INDEX NAME)				




RN 84591-05-9 CAPLUS
 CN 4-Pyrimidinecarboxylic acid, 3-(3-amino-3-imino-1-oxopropyl)hexahydro-2,6-dioxo- (9CI) (CA INDEX NAME)



RN 84591-06-0 CAPLUS
 CN 4-Pyrimidinecarboxylic acid, 3-(3-amino-3-imino-1-oxopropyl)hexahydro-5-methyl-2,6-dioxo- (9CI) (CA INDEX NAME)

10/715,331



L6 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1979:23041 CAPLUS
 DN 90:23041
 TI Penicillin derivatives
 IN Morita, Yoshimi; Komata, Kenzo; Oya, Junichi
 PA Mitsubishi Chemical Industries Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 5 pp.
 CODEN: JKXXAF

DT Patent
 LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 53073587	A	19780630	JP 1976-148191	19761209
PRAI	JP 1976-148191	A	19761209		


AB Acylation of ampicillin (I) by stirring QOH (R1 = CO₂CH₂Ph) (II) with Et₃N and ClCO₂Bu-iso 30 min at 0°, and then stirring with I and Et₃N at -30° and 2 h at 0° gave 54% III-2H₂O (R = Q, R1 = PhCH₂O₂C) (III). Deprotection of III by H₂-Pd-BaCO₃ gave 50% III (R = Q, R1 = H) (IV) (as K salt). The min. inhibitory concns. of III against Staphylococcus aureus and that of IV against Proteus vulgaris were 0.93 and >6.2 µg/mL, resp.

IT 68588-94-3

RL: RCT (Reactant); RACT (Reactant or reagent)
 (acylation of ampicillin by)

RN 68588-94-3 CAPLUS

CN 1,6(2H)-Pyrimidinedicarboxylic acid, tetrahydro-4-oxo-, 1-(phenylmethyl) ester (9CI) (CA INDEX NAME)



L6 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1962:18537 CAPLUS
 DN 56:18537

OREF 56:3559e-i,3560a-i,3561a

TI Synthesis of two peptides containing methylene-L-asparagine

AU Stammer, Charles H.

CS Merck Sharp & Dohme Research Labs., Rahway, NJ

SO Journal of Organic Chemistry (1961), 26, 2556-60

CODEN: JOCEAH; ISSN: 0022-3263

DT Journal

LA Unavailable

OS CASREACT 56:18537

AB -Finely powdered L-H₂NCOCH₂CH(NH₂)CO₂H.H₂O (I) (100 g.) heated in 700 ml. H₂O at 75° 1 hr. filtered, treated at 45° with 54 g. 37% aqueous HCHO, the mixture kept 20 min. before diluting with 2 ml. MeOH, kept 2 hrs. at 0°, the product washed with MeOH, and dried in vacuo at 50° yielded 59.5% material, m. 210-60°, [α]_{25D} -63.5° (c 1.07, H₂O), R_f 0.28, 0.35, 0.40 (solvent C, 20:5:8 MeCOEt-C₅H₅N-H₂O, located with ninhydrin). The material (5 g.) recrystd. from 170 ml. H₂O and 100 ml. MeOH at 28° gave 3.0 g. methylene-L-asparagine (II), m. 210-60° (decomposition), [α]_{25D} -73.5° (c 2.04, H₂O), R_f 0.50 (solvent C), λ 3.1, 5.95-6.2 μ . I (30.0 g.) in 200 ml. N LiOH and 18 ml. 37% aqueous HCHO kept 48 hrs. at 20°, acidified with 13 ml. AcOH, slowly diluted with 500 ml. absolute alc., refrigerated 16 hrs., and the product washed with alc. and Et₂O gave 53% material, [α]_{25D} -62.5° (c 2.46, H₂O), [α]_{25D} -103.5° (c 7.25, H₂O containing 1 equivalent NaOH), R_f 0.31, 0.44 (solvent C) (L-asparagine, R_f 0.30;

L-aspartic acid, R_f 0.32). The material stirred 2 hrs. at 25° in 350 ml. H₂O, the filtered solution diluted with 350 ml. H₂O, refrigerated 16 hrs., and filtered gave 7.2 g. crystalline II. II (254 mg.) in 25.0 ml. 0.89N LiOH kept 24 hrs. at 25°, the solution (constant optical rotation, [α]_{25D} -5.88°) adjusted to pH 6 with 2 ml. AcOH, lyophilized, and the residue crystallized from 11 ml. 4:7 H₂O-alc. gave 173 mg. crystalline material, R_f 0.22 (solvent A, upper phase, 4:1:5 BuOH-AcOH-H₂O), R_f 0.23, R_f 0.32 (solvent C). Dimedon (4 millimoles) in 75 ml. warm H₂O and 2 millimoles II kept 16 hrs. at 25°, filtered from the dimedon-HCHO adduct (524 mg.), the filtrate lyophilized, the residue extracted with hot alc., the insol. portion taken up in hot H₂O, diluted dropwise with alc., the crystalline precipitate washed with alc., and dried gave I. II (5.0 g.) in 50 ml.

half-saturated aqueous KHCO₃ stirred magnetically with 4.9 ml. PhCH₂OCOC₂ 2.5 hrs. at 25°, the solution washed with Et₂O, adjusted to pH 1.5 with concentrated HCl, the precipitated oil extracted into 150 ml. EtOAc, the dried extract evaporated

to 100 ml., and the product washed with EtOAc yielded 59% carbobenzyloxymethylene-L-asparagine (III), m. 135-8°, [α]_{25D} -30° (c 1.55, H₂O). III (2.78 g.) in 25.0 ml. 2.13N LiOH kept 10 days at 25°, the solution (constant optical rotation, [α]_{25D} -0.28°) acidified with 3 ml. AcOH, lyophilized, the residue extracted with hot alc., and the insol. solid dried gave material, R_f 0.33 (solvent C, DL-aspartic acid, 0.36). (C₆H₁₁N:)₂C (IV) (30 millimoles) and 30 millimoles p-HOC₆H₄CH₂CH(NH₂)CO₂Me in 50 ml. dry HCONMe₂ stirred 1 hr. at 0° (ice bath) with addition of 30 millimoles III in 30 ml. dry HCONMe₂, the mixture stirred 16 hrs. at 25°, filtered at 0° from 4.55 g. (C₆H₁₁NH)CO (V), the filtrate evaporated, the residue taken up in 200 ml. EtOAc, the solution washed with N HCl and saturated aqueous KHCO₃, the dried

organic phase evaporated, and the residue crystallized from EtOAc yielded 45.5% ester,

m. 163-5°, $[\alpha]_{24D} -45.7^\circ$ (c 1.05, MeOH), recrystd. from 1:3 Me₂CHOH-H₂O to give carbobenzyloxymethylene-L-asparaginyl-L-tyrosine Me ester (VI), m. 163-5°, $[\alpha]_{25D} -48^\circ$ (c 1.0, MeOH), Rf 1.0 (solvent C, visualized with diazotized p-H₂NC₆H₄SO₃H), 0.89 (solvent C, diazotized p-H₂NC₆H₄SO₃H). Under the same conditions H₂NCOCH₂CH(CO₂H)NHOCOCH₂Ph (VII) was coupled with tyrosine Me ester to yield 27% carbobenzyloxy-L-asparaginyl-L-tyrosine Me ester, m. 197-9°, $[\alpha]_{25D} 1.96^\circ$ (c 1.02, MeOH). Conversion of VI to the free L-asparaginyl-L-tyrosine failed. The ester group was saponified in 0.5N NaOH. VI (0.50 millimole) kept 2 hrs. at 25° in 2.0 ml. 0.5N NaOH (ring chromatographic procedures showed that saponification was

complete

in 15 min. and that the methylene-L-asparaginyl ring was not destroyed in 2 hrs.), the mixture acidified with 1.0 ml. 1.0N HCl, the separated oil

extracted

into EtOAc, the residue on evaporation of the extract (228 mg.) taken up in hot Me₂CHOH, the solution diluted with H₂O, and kept 3 hrs. at 25° prior to refrigeration yielded 50% material, washed with 1:4 Me₂CHOH-H₂O and dried to give carbobenzyloxymethylene-L-asparaginyl-L-tyrosine (VIII), m. 119-22° (Me₂CHOH-H₂O), $[\alpha]_{25D} -25.5^\circ$ (c 1.06, C₅H₅N), Rf 0.88 (solvent C), 0.31 (solvent B, 1:1 BuOH-1.5N NH₄OH, upper phase). Reductive removal of the PhCH₂OCO group from VIII gave a mixture of products, which reacted with ninhydrin and diazotized p-H₂NC₆H₄SO₃H. Treatment of the mixture with aqueous dimedon gave only 47% dimedon-HCHO adduct and a new mixture of peptides. The complexity of the mixture made further investigation impractical. A 2nd methylene-L-asparaginyl peptide was obtained by reaction of the mixed anhydride of III with the Na salt of nitro-L-arginine (IX). III (80 millimoles) in 300 ml. 1:1 tetrahydrofuran-dioxane stirred mechanically (ice-MeOH bath) with successive addition of 80 millimoles NEt₃ and 80 millimoles ClCO₂CH₂CHMe₂, the mixture stirred 20 min. before addition of 100 millimoles IX and 110 millimoles NEt₃ in 300 ml. ice-cold H₂O in 5 min., the mixture stirred 4 hrs. with warming to 25°, stripped of organic solvents, acidified with concentrated HCl, the mixture extracted into 1:1 BuOH-EtOAc, and the residue

on evaporation

trituated with hot EtOAc gave 26.4 g. product, Rf 0.23, 0.35, 0.49 (solvent B, ultraviolet visualization). The product (10 g.) in 75 ml. hot 1:1 Et₂O-H₂O filtered and the solution kept 1 week at 25° gave 4.5 g. crystalline material, m. 199-202°, recrystd. from 3:7 alc.-H₂O to give carbobenzyloxymethylene-L-asparaginyl-nitro-L-arginine (X), m. 202-4°, Rf 0.82, 0.70, and 0.20 (in solvents C, A, and B, resp.), $[\alpha]_{25D} -27.5^\circ$ (c 2.18, 0.1N NaOH). X (2.5 g.) in 60 ml. 5:1 MeOH-H₂O hydrogenated 16 hrs. at 25°/40 lb./sq. in. over 2.5 g. 10% Pd-C, the filtered solution evaporated, the residue taken up in 50 ml. H₂O, the solution lyophilized, and the residue (1.30 g.) crystallized from 12 ml. hot

MeOH

yielded 72% methylene-L-asparaginyl-L-arginine-MeOH (XI), m. 160-5° (decomposition), Rf 0.29 (solvent C). XI (250 mg.) in 1 ml. H₂O diluted with 1 ml. Me₂CHOH, seeded, and diluted with 3 ml. MeOH gave 177 mg. crystalline material, m. 163-5°, $[\alpha]_{23D} -31^\circ$ (c 1.0, 0.1N HCl), retaining MeOH after drying 2 hrs. at 78°/0.1 mm. over Drierite. XI treated with aqueous dimedon gave a peptide product showing 3 ninhydrin-pos. components. Attempts to purify the mixture failed. To investigate the possibility of carbamido group participation in the coupling reaction, VII was treated with IV in the absence of tyrosine Me ester. VII (10 millimoles) in 27 ml. dry HCONMe₂ added in 15 min. with magnetic stirring to 10 millimoles IV in 12 ml. ice-cold HCONMe₂, the mixture kept 20 hrs. at 25° with precipitation of solid V, the mixture treated with 10 millimoles L-tyrosine Me ester in 10 ml. warm HCONMe₂, kept 4 hrs. at 25°, filtered from 2.07 g. V, the filtrate evaporated, the residue

taken up in 100 ml. EtOAc, the solution washed with 50 ml. half-saturated aqueous

KHCO₃ with removal of 2.0 g. acidic products, the solution freed from 0.8 g. ester by washing with 50 ml. 2.5N HCl, the washed solution evaporated, and the neutral material (0.5 g., R_f 0.95 in solvent B) taken up in MeOH gave crystalline carbobenzyloxy-L-asparaginyl-L-tyrosine Me ester, m. 200-12°. The acidic product crystallized from 25 ml. ClCH₂CH₂Cl yielded 42% material, m. 126-8°, recrystd. from 60 ml. (ClCH₂)₂ to give 880 mg. carbobenzyloxy-cyano-L-alanine, m. 126-8°, [α]_D²⁰ -19° (c 1.26, MeOH), λ 4.43 μ. The product may be converted readily with HBr-AcOH to asparagine and may have utility in asparaginyl peptide synthesis.


IT 68588-94-3P, 1,6(2H)-Pyrimidinedicarboxylic acid, tetrahydro-4-oxo-, 1-benzyl ester

RL: PREP (Preparation)

(preparation of)

RN 68588-94-3 CAPLUS

CN 1,6(2H)-Pyrimidinedicarboxylic acid, tetrahydro-4-oxo-, 1-(phenylmethyl) ester (9CI) (CA INDEX NAME)



10/715,331

=> => d his

(FILE 'HOME' ENTERED AT 20:04:56 ON 21 JUN 2007)

FILE 'REGISTRY' ENTERED AT 20:05:04 ON 21 JUN 2007

L1 STRUCTURE UPLOADED

L2 0 S L1 SSS SAM

L3 STRUCTURE UPLOADED

L4 0 S L3 SSS SAM

L5 15 S L3 SSS FUL

FILE 'CAPLUS' ENTERED AT 20:07:07 ON 21 JUN 2007

L6 11 S L5

FILE 'CAOLD' ENTERED AT 20:07:37 ON 21 JUN 2007


=> s l5

L7 1 L5

=> d l7 bib,hitstr

10/715,331

L7 ANSWER 1 OF 1 CAOLD COPYRIGHT 2007 ACS on STN
AN CA56:3559e CAOLD
TI hydrolysis of peptide bonds
AU Niemann, Albert
TI synthesis of two peptides containing methylene-L-asparagine
AU Stammer, Charles H.
IT 68588-94-3
RN 68588-94-3 CAOLD
CN 1,6(2H)-Pyrimidinedicarboxylic acid, tetrahydro-4-oxo-, 1-(phenylmethyl)
ester (9CI) (CA INDEX NAME)



10/715,331

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

3.47

235.12

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-8.58

STN INTERNATIONAL LOGOFF AT 20:07:56 ON 21 JUN 2007